Is a dose of 50 mg twice daily lamotrigine equivalent to 250 mg twice daily levetiracetam (Keppra)?

Direct Answer to Lamotrigine-Keppra Conversion Question

There is no established dose equivalency between lamotrigine 50 mg twice daily and levetiracetam (Keppra) 250 mg twice daily - these medications have completely different mechanisms of action, pharmacokinetics, and dose-response relationships, making direct dose conversion inappropriate and potentially dangerous.

Why Direct Conversion is Not Appropriate

Different Mechanisms and Dose Ranges

Lamotrigine and levetiracetam are fundamentally different antiepileptic drugs that cannot be converted using a simple ratio:

• Lamotrigine therapeutic range: 200-400 mg/day for adults with partial seizures, with responder rates of 20-34% at 300-500 mg/day 1
• Levetiracetam therapeutic range: 1,000-3,000 mg/day for adults, with responder rates of 22-33% at 1,000 mg/day and up to 39.8% at 3,000 mg/day 1

Your proposed doses (50 mg BD lamotrigine = 100 mg/day total; 250 mg BD Keppra = 500 mg/day total) are both substantially below therapeutic levels for either medication.

Evidence Against Simple Equivalency

The LaLiMo trial directly compared these medications and found no simple dose relationship 2. When titrated to therapeutic doses (200 mg/day lamotrigine vs 2,000 mg/day levetiracetam), seizure-free rates were similar (64.0% vs 67.5%), but this required a 10-fold difference in absolute dose.

Proper Approach to Switching

If Switching from Lamotrigine to Levetiracetam:

1. Start levetiracetam at therapeutic dose: 1,000 mg/day (500 mg BID) per FDA labeling 3
2. Titrate up by 1,000 mg/day every 2 weeks to target of 2,000-3,000 mg/day
3. Maintain lamotrigine during titration to prevent breakthrough seizures
4. Taper lamotrigine slowly only after levetiracetam reaches therapeutic levels

Critical Pitfalls to Avoid:

• Never assume a 5:1 ratio (your proposed 250 mg Keppra for 50 mg lamotrigine) - this has no scientific basis
• Don't use subtherapeutic doses: 500 mg/day levetiracetam is below the minimum effective dose of 1,000 mg/day 3
• Don't abruptly discontinue lamotrigine: Risk of breakthrough seizures and potential status epilepticus

Drug Interaction Considerations

The FDA label confirms these medications do not interact pharmacokinetically 3. Levetiracetam does not affect lamotrigine plasma concentrations, and vice versa, making cross-titration safer from an interaction standpoint but not eliminating the need for proper dosing.

Clinical Context Matters

If your patient is currently on lamotrigine 50 mg BD (100 mg/day total):

• This is a subtherapeutic dose for most epilepsy types
• Either increase lamotrigine to therapeutic range (200-400 mg/day) OR
• Switch to levetiracetam at proper therapeutic dose (1,000-3,000 mg/day)
• Starting Keppra at only 250 mg BD will leave the patient undertreated

The 20-fold dose difference between these medications (100 mg lamotrigine vs 2,000 mg levetiracetam for comparable efficacy) reflects their completely different pharmacological properties, not a conversion factor to be applied at subtherapeutic doses.